Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways

(2019) Joseph Yi Zhou et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

(2018) K. Cusi et al.   DIABETIC MEDICINE

Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet

(2018) Wei Zhu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Liraglutide modulates gut microbiota and reduces NAFLD in obese mice

(2018) GV Moreira et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway

(2016) Qin He et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

(2016) Mark M. Smits et al.   DIABETES CARE

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

(2016) Mark M. Smits et al.   DIABETOLOGIA

Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study

(2016) Jean-Michel Petit et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

(2016) Jeffrey Cui et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

(2016) Zhixia Li et al.   PLoS One

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

(2015) An Tang et al.   DIABETES CARE

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Fatty Pancreas, Insulin Resistance and β-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging

(2014) Vincent Wai-Sun Wong et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and Δ-5-desaturase index in a murine model of non-alcoholic steatohepatitis

(2014) TAKUMI KAWAGUCHI et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma

(2014) Mika Hori et al.   Clinical and Translational Gastroenterology

Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease

(2013) N. S. Patel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Association between non-alcoholic fatty pancreatic disease (nafpd) and the metabolic syndrome: case–control retrospective study

(2013) Wan-Chen Wu et al.   Cardiovascular Diabetology

Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis

(2013) Scott B. Reeder   HEPATOLOGY

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

(2013) Mazen Noureddin et al.   HEPATOLOGY

Use of AUDIT-Based Measures to Identify Unhealthy Alcohol Use and Alcohol Dependence in Primary Care: A Validation Study

(2012) J. Aaron Johnson et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice

(2012) Jinmi Lee et al.   PLoS One

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

(2011) Jamie E. Mells et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents

(2011) Joel E. Lavine   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy

(2011) Shvetank Sharma et al.   PLoS One

Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c

(2010) P. Ferré et al.   DIABETES OBESITY & METABOLISM

Clinical implications of fatty pancreas: Correlations between fatty pancreas and metabolic syndrome

(2009) Jun Seok Lee et al.   WORLD JOURNAL OF GASTROENTEROLOGY